We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.63%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$25.6M
Cap. Flow
-$33.2M
Cap. Flow %
-30.38%
Top 10 Hldgs %
43.42%
Holding
74
New
7
Increased
2
Reduced
48
Closed
7

Top Buys

Rank Stock Value
1
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$2.22M
2
RXDX
Ignyta, Inc.
RXDX
+$1.38M
3
CKPT
Checkpoint Therapeutics
CKPT
+$1.16M
4
KPTI icon
Karyopharm Therapeutics
KPTI
+$987K
5
LOXO
Loxo Oncology, Inc
LOXO
+$765K

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$4.61M
2
IBB icon
iShares Biotechnology ETF
IBB
+$3.69M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.62M
4
ALKS icon
Alkermes
ALKS
+$2.41M
5
INCY icon
Incyte
INCY
+$2.22M

Sector Composition

Rank Sector Weight
1 Healthcare 63.93%
2 Real Estate 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIB icon
1
ProShares Ultra NASDAQ Biotechnology
BIB
$82.9M
$6.97M 6.38%
130,500
+45,500
+54% +$2.22M
MRK icon
2
Merck
MRK
$322B
$5.36M 4.91%
87,718
– –
XBI icon
3
State Street SPDR S&P Biotech ETF
XBI
$10B
$5.02M 4.6%
65,000
-65,000
-50% -$4.61M
XBI icon
4
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$5.02M 4.6%
+65,000
New +$4.61M
BMY icon
5
Bristol-Myers Squibb
BMY
$129B
$5.01M 4.59%
90,000
– –
ALXN
6
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$4.26M 3.9%
35,000
– –
AZN icon
7
AstraZeneca
AZN
$269B
$4.09M 3.75%
60,000
– –
ALNY icon
8
Alnylam Pharmaceuticals
ALNY
$38.3B
$3.92M 3.59%
49,095
-41,026
-46% -$2.62M
IBB icon
9
iShares Biotechnology ETF
IBB
$9.45B
$3.88M 3.55%
37,500
-37,500
-50% -$3.69M
IBB icon
10
PUT
iShares Biotechnology ETF
IBB
$9.45B
$3.88M 3.55%
+37,500
New +$3.69M
PFE icon
11
Pfizer
PFE
$143B
$3.77M 3.46%
118,364
– –
GSK icon
12
GSK
GSK
$107B
$2.59M 2.37%
48,000
– –
BMY icon
13
CALL
Bristol-Myers Squibb
BMY
$129B
$2.51M 2.3%
45,000
– –
ALKS icon
14
Alkermes
ALKS
$8.11B
$2.47M 2.26%
42,623
-41,567
-49% -$2.41M
VRTX icon
15
Vertex Pharmaceuticals
VRTX
$123B
$2.45M 2.24%
18,994
-15,012
-44% -$1.81M
BIB icon
16
PUT
ProShares Ultra NASDAQ Biotechnology
BIB
$82.9M
$2.27M 2.08%
+42,500
New +$2.07M
INCY icon
17
Incyte
INCY
$25.8B
$2.25M 2.06%
17,832
-17,408
-49% -$2.22M
IONS icon
18
Ionis Pharmaceuticals
IONS
$8.93B
$2.23M 2.04%
43,867
-35,033
-44% -$1.63M
REGN icon
19
Regeneron Pharmaceuticals
REGN
$72.9B
$2.23M 2.04%
4,532
-3,503
-44% -$1.53M
MTD icon
20
Mettler-Toledo International
MTD
$28.1B
$2.12M 1.94%
3,594
-3,594
-50% -$1.97M
QGEN icon
21
Qiagen
QGEN
$8.62B
$1.9M 1.74%
53,562
-51,837
-49% -$1.75M
NKTR icon
22
Nektar Therapeutics
NKTR
$2.39B
$1.9M 1.74%
6,480
-5,939
-48% -$1.72M
CELG
23
DELISTED
Celgene Corp
CELG
$1.86M 1.71%
14,344
-13,853
-49% -$1.7M
SGEN
24
DELISTED
Seagen Inc. Common Stock
SGEN
$1.82M 1.66%
35,093
-34,419
-50% -$2.19M
RXDX
25
DELISTED
Ignyta, Inc.
RXDX
$1.76M 1.62%
+170,500
New +$1.38M
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q2 2017 Portfolio in Review

As of Q2 2017, Opus Point Partners Management held 74 positions worth $109M, down 19% from $135M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opus Point Partners Management withdrew a net $33.2M in Q2 2017, closing 7 positions and reducing 48 holdings. Its most notable exit was Portola Pharmaceuticals, Inc., an estimated $980K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 74% a quarter earlier, followed by Real Estate.

Against the trend, Opus Point Partners Management opened a new position in Ignyta, Inc. worth $1.76M.

  • Opus Point Partners Management's largest Q2 2017 buy was Ignyta, Inc.: 170,500 shares worth $1.76M.
  • Opus Point Partners Management added most to ProShares Ultra NASDAQ Biotechnology in Q2 2017, an estimated $2.22M increase.
  • Opus Point Partners Management's biggest Q2 2017 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $4.61M.
  • Opus Point Partners Management fully exited Portola Pharmaceuticals, Inc. in Q2 2017, selling an estimated $980K.
  • Opus Point Partners Management's ten largest holdings make up 43% of its $109M portfolio in Q2 2017.
  • Opus Point Partners Management opened 7 new positions and closed 7 in Q2 2017.
  • Opus Point Partners Management's portfolio value fell 19% quarter-over-quarter to $109M.

Based on Opus Point Partners Management's 13F filing for Q2 2017, filed 14 Aug 2017.